Citations

Mayo Clinic

Showing 10 of 108551 citations.

The 3D Revolution in Cancer Discovery
Wang, Linghua , Li, Mingyao , Hwang, Tae Hyun

Cancer Discovery | April 4, 2024 | Volume: 14 | Issue: 4 | Pages: 625-629

10.1158/2159-8290.cd-23-1499 | PMID 38571426 Get It

Summary: The transition from 2D to 3D spatial profiling marks a revolutionary era in cancer research, offering unprecedented potential to enhance cancer diagnosis and treatment. This commentary outlines the experimental and computational advancements and challenges in 3D spatial molecular profiling, underscoring the innovation needed in imaging tools, software, artificial intelligence, and machine learning to overcome implementation hurdles and harness the full potential of 3D analysis in the field.
Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants
Orlandi, Francesca, Carlos, Arenn F. , Ali, Farwa , Duffy, Joseph R. , Botha, Hugo , Stephens, Yehkyoung C. , Schwarz, Christopher G. , Jack, Clifford R. , Agosta, Federica , Josephs, Keith A. , Whitwell, Jennifer L. , Duffy, Joseph R , Botha, Hugo , Schwarz, Christopher G , Jack, Clifford R , Agosta, Federica , Filippi, Massimo , Dickson, Dennis W , Josephs, Keith A , Whitwell, Jennifer , Carlos, Arenn F , Clark, Heather M. , Utianski, Rene L. , Machulda, Mary M. , Senjem, Matthew L. , Filippi, Massimo , Dickson, Dennis W.

Brain Communications | April 4, 2024 | Volume: 6 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcae113 | PMID 38660629 Get It

Abstract Progressive supranuclear palsy is a neurodegenerative disease characterized by the deposition of four-repeat tau in neuronal and glial lesions in the brainstem, cerebellar, subcortical and cortical brain regions. There are varying clinical presentations of progressive supranuclear palsy with different neuroimaging signatures, presumed to be due to different topographical distributions and burden of tau. The classic Richardson syndrome presentation is considered a subcortical variant, whilst progressive supranuclear palsy with predominant speech and language impairment is considered a cortical variant, although the pathological underpinnings of these variants are unclear. In this case-control study, we aimed to determine whether patterns of regional tau pathology differed between these variants and whether tau burden correlated with neuroimaging. Thirty-three neuropathologically confirmed progressive supranuclear palsy patients with either the Richardson syndrome (n = 17) or speech/language (n = 16) variant and ante-mortem magnetic resonance imaging were included. Tau lesion burden was semi-quantitatively graded in cerebellar, brainstem, subcortical and cortical regions and combined to form neuronal and glial tau scores. Regional magnetic resonance imaging volumes were converted to Z-scores using 33 age- and sex-matched controls. Diffusion tensor imaging metrics, including fractional anisotropy and mean diffusivity, were calculated. Tau burden and neuroimaging metrics were compared between groups and correlated using linear regression models. Neuronal and glial tau burden were higher in motor and superior frontal cortices in the speech/language variant. In the subcortical and brainstem regions, only the glial tau burden differed, with a higher burden in globus pallidus, subthalamic nucleus, substantia nigra and red nucleus in Richardson’s syndrome. No differences were observed in the cerebellar dentate and striatum. Greater volume loss was observed in the motor cortex in the speech/language variant and in the subthalamic nucleus, red nucleus and midbrain in Richardson’s syndrome. Fractional anisotropy was lower in the midbrain and superior cerebellar peduncle in Richardson’s syndrome. Mean diffusivity was greater in the superior frontal cortex in the speech/language variant and midbrain in Richardson’s syndrome. Neuronal tau burden showed associations with volume loss, lower fractional anisotropy and higher mean diffusivity in the superior frontal cortex, although these findings did not survive correction for multiple comparisons. Results suggest that a shift in the distribution of tau, particularly neuronal tau, within the progressive supranuclear palsy network of regions is driving different clinical presentations in progressive supranuclear palsy. The possibility of different disease epicentres in these clinical variants has potential implications for the use of imaging biomarkers in progressive supranuclear palsy.
Rural-urban Differences in Long-term Mortality and Readmission Following COVID-19 Hospitalization, 2020 to 2023
Yousufuddin, Mohammed , Barkoudah, Ebrahim , Badr, Fatimazahra, Khandelwal, Kanika , Manyara, Warren, Abdalrhim, Ahmed D., Issa, Meltiady , Bhagra, Sumit , Mahmood, Maryam , Murad, Mohammad H, Mahmood, Maryam , Sharma, Umesh, Murad, M. Hassan

Open Forum Infectious Diseases | April 3, 2024 | Volume: 11 | Issue: 5 | Pages: No page available

10.1093/ofid/ofae197 | PMID 38698896 Get It

Abstract Background We compared long-term mortality and readmission rates after COVID-19 hospitalization based on rural-urban status and assessed the impact of COVID-19 vaccination introduction on clinical outcomes by rurality. Methods The study comprised adults hospitalized for COVID-19 at 17 hospitals in 4 US states between March 2020 and July 2022, followed until May 2023. The main analysis included all patients, whereas a sensitivity analysis focused on residents from 4 states containing 17 hospitals. Additional analyses compared the pre- and postvaccination periods. Results The main analysis involved 9325 COVID-19 hospitalized patients: 31% were from 187 rural counties in 31 states; 69% from 234 urban counties in 44 states; the mean age was 65 years (rural, 66 years; urban, 64 years); 3894 women (rural, 41%; urban, 42%); 8007 Whites (rural, 87%; urban, 83%); 1738 deaths (rural, 21%; urban, 17%); and 2729 readmissions (rural, 30%; urban, 29%). During a median follow-up of 602 days, rural residence was associated with a 22% higher all-cause mortality (log-rank, P < .001; hazard ratio, 1.22; 95% confidence interval, 1.10-1.34, P < .001), and a trend toward a higher readmission rate (log-rank, P = .038; hazard ratio, 1.06; 95% confidence interval, .98-1.15; P = .130). The results remained consistent in the sensitivity analysis and in both pre- and postvaccination time periods. Conclusions and Relevance Patients from rural counties experienced higher mortality and tended to be readmitted more frequently following COVID-19 hospitalization over the long term compared with those from urban counties, a difference that remained even after the introduction of COVID-19 vaccines.
Risk of Neuroinflammatory Diseases Among New Recipients of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs
Casey, Maximilian , Pannu, Sonia, Bajwa, Saffia, Duarte‐García, Alí , Putman, Michael , Duarte-García, Alí

Arthritis Care & Research | April 3, 2024 | Volume: 76 | Issue: 8 | Pages: 1203-1209

10.1002/acr.25340 | PMID 38570894 Get It

ObjectiveNeuroinflammatory adverse events have been observed among new users of tumor necrosis factor (TNF) inhibitors. No studies to date have compared the real‐world risk of TNFs with other new users of biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs). The objective of this study is to describe the risk of neuroinflammatory disease after initiation b/tsDMARDs.MethodsThis new user comparative effectiveness cohort study used a large US‐based electronic health records database to describe the unadjusted incidence of neuroinflammatory adverse events over a 3‐year period. The cohort included patients with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis initiating treatment with a TNF inhibitor (n = 93,661) or other b/tsDMARD (n = 38,354).ResultsAmong 132,015 patients included in the analysis, the most common first biologic agent was a TNF inhibitor; the unadjusted incidence of neuroinflammatory events was numerically lower among new users of TNF inhibitors (incidence 1.34 per 1,000 patient‐years) as compared with the combined non‐TNF group (1.69 per 1,000 patient‐years). There was no significant association between TNF exposure and neuroinflammatory events as compared with the combined non‐TNF b/tsDMARDs overall (hazard ratio 1.01; 95% confidence interval 0.75–1.36) and within each disease group.ConclusionThe overall risk of neuroinflammatory events among new users of TNF inhibitors did not differ substantially as compared with new users of other b/tsDMARDs. Meta‐analyses of randomized trials should be conducted to corroborate these findings, which may be affected by channeling bias.
Industry payments to American Society of Hematology Clinical Practice Guideline authors
Jacobs, Jeremy W. , Booth, Garrett S. , Adkins, Brian D. , Martin, Amarilis , Lundberg, George D., Glover, Raeshun T, Khan, Shazia S , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Stephens, Laura D. , Silver, Julie K. , Woo, Jennifer S.

Blood Advances | April 3, 2024 | Volume: 8 | Issue: 13 | Pages: 3549-3552

10.1182/bloodadvances.2023012527 | PMID 38569136 Get It

Fresnel Zone-Based Voting With Capsule Networks for Human Activity Recognition From Channel State Information
Djogo, Radomir , Salehinejad, Hojjat , Hasanzadeh, Navid , Valaee, Shahrokh

IEEE Internet of Things Journal | April 3, 2024 | Volume: 11 | Issue: 13 | Pages: 23309-23321

10.1109/jiot.2024.3384872 Get It

Early Choriocapillaris Loss in a Porcine Model of RPE Cell Debridement Precedes Pathology That Simulates Advanced Macular Degeneration
Iezzi, Raymond , Scruggs, Brittni A. , Gandhi, Jarel K. , Zenti, Francesca N., Shafi, Noah, Berger, Aubrey , Marmorstein, Alan D. , Gandhi, Jarel, Scruggs, Brittni A , Marmorstein, Alan D

Investigative Opthalmology & Visual Science | April 3, 2024 | Volume: 65 | Issue: 4 | Pages: 8

10.1167/iovs.65.4.8 | PMID 38568620 Get It

Accurate Patient Alignment without Unnecessary Imaging Dose via Synthesizing Patient-specific 3D CT Images from 2D kV Images
Liu, Wei , Ding, Yuzhen , McGee, L.A. , Rwigema, Jean‐Claude M. , Vora, Sujay A., Wong, William W. , Foote, Robert L. , Patel, Samir H. , Liu, Wei

No container title available | April 3, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4086699/v1 Get It

Abstract In radiotherapy, 2D orthogonally projected kV images are used for patient alignment when 3D-on-board imaging(OBI) unavailable. But tumor visibility is constrained due to the projection of patient’s anatomy onto a 2D plane, potentially leading to substantial setup errors. In treatment room with 3D-OBI such as cone beam CT(CBCT), the field of view(FOV) of CBCT is limited with unnecessarily high imaging dose, thus unfavorable for pediatric patients. A solution to this dilemma is to reconstruct 3D CT from kV images obtained at the treatment position. Here, we propose a dual-models framework built with hierarchical ViT blocks. Unlike a proof-of-concept approach, our framework considers kV images as the solo input and can synthesize accurate, full-size 3D CT in real time(within milliseconds). We demonstrate the feasibility of the proposed approach on 10 patients with head and neck(H\&N) cancer using image quality(MAE:<45HU), dosimetric accuracy(Gamma passing rate(2%/2mm/10%):>97%) and patient position uncertainty(shift error:<0.4mm). The proposed framework can generate accurate 3D CT faithfully mirroring real-time patient position, thus significantly improving patient setup accuracy, keeping imaging dose minimum, and maintaining treatment veracity.
Cutaneous Stigmata of Bacterial Endocarditis
Castrichini, Matteo , Haemmerle, Robert , Tosh, Pritish K. , Haemmerle, Robert J , Castrichini, Matteo

JAMA Dermatology | April 3, 2024 | Volume: 160 | Issue: 5 | Pages: 564

10.1001/jamadermatol.2024.0481 | PMID 38568680 Get It

This case report describes Osler nodes and Janeway lesions on a man in his 70s.
CSF biomarkers of immune activation and Alzheimer’s disease for predicting cognitive impairment risk in the elderly
Shue, Francis , White, Launia J. , Hendrix, Rachel , Ulrich, Jason D. , Henson, Rachel L. , Knight, William D., Martens, Yuka A. , Wang, Ni , Starling, Skylar C , Ren, Yingxue , Asmann, Yan W. , Syrjanen, Jeremy A. , Vassilaki, Maria , Sung, Yun Ju , Petersen, Ronald C. , Kanekiyo, Takahisa , Ulrich, Jason , Asmann, Yan W , Syrjanen, Jeremy A , Vassilaki, Maria , Mielke, Michelle M , Timsina, Jigyasha , Sung, Yun Ju , Cruchaga, Carlos , Holtzman, David M , Bu, Guojun , Petersen, Ronald C , Kanekiyo, Takahisa , Shue, Francis , Roy, Bhaskar, Xiong, Chengjie , Mielke, Michelle M. , Holtzman, David M. , Bu, Guojun , Heckman, Michael G.

Science Advances | April 3, 2024 | Volume: 10 | Issue: 14 | Pages: No page available

10.1126/sciadv.adk3674 | PMID 38569027 Get It

The immune system substantially influences age-related cognitive decline and Alzheimer’s disease (AD) progression, affected by genetic and environmental factors. In a Mayo Clinic Study of Aging cohort, we examined how risk factors like APOE genotype, age, and sex affect inflammatory molecules and AD biomarkers in cerebrospinal fluid (CSF). Among cognitively unimpaired individuals over 65 ( N = 298), we measured 365 CSF inflammatory molecules, finding age, sex, and diabetes status predominantly influencing their levels. We observed age-related correlations with AD biomarkers such as total tau, phosphorylated tau-181, neurofilament light chain (NfL), and YKL40. APOE4 was associated with lower Aβ42 and higher SNAP25 in CSF. We explored baseline variables predicting cognitive decline risk, finding age, CSF Aβ42, NfL, and REG4 to be independently correlated. Subjects with older age, lower Aβ42, higher NfL, and higher REG4 at baseline had increased cognitive impairment risk during follow-up. This suggests that assessing CSF inflammatory molecules and AD biomarkers could predict cognitive impairment risk in the elderly.